Repros Therapeutics, Inc. (RPRX): Looks like the nail was hit on the head...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	3405
Boards Moderated	0
Alias Born	07/28/2013

cjf913913

Re: cjf913913 post# 8222

Thursday, 04/21/2016 12:34:08 PM

Thursday, April 21, 2016 12:34:08 PM

Looks like the nail was hit on the head there.......

Rprx

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent RPRX News

Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 04/19/2024 12:15:00 PM
Royalty Pharma Declares Second Quarter 2024 Dividend • GlobeNewswire Inc. • 04/17/2024 12:15:00 PM
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 09:15:00 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 02:05:28 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 12:33:43 PM
Royalty Pharma Reports Q4 and Full Year 2023 Results • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 12:01:30 PM
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 • GlobeNewswire Inc. • 01/30/2024 09:15:00 PM
Royalty Pharma Announces Dividend Increase • GlobeNewswire Inc. • 01/19/2024 01:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:18:52 PM
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:31:02 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/03/2024 09:30:54 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 09:29:43 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:31:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 06:05:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 09:30:29 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:02 PM
Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/13/2023 09:47:54 PM
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference • GlobeNewswire Inc. • 11/27/2023 09:15:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:16:52 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 10:13:26 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 12:35:11 AM
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program • GlobeNewswire Inc. • 11/13/2023 01:10:00 PM
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program • Business Wire • 11/13/2023 01:00:00 PM

More RPRX News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover